BB Biotech Stock Forward View - Triple Exponential Smoothing
| BION Stock | CHF 46.10 1.45 3.25% |
Momentum
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 6.92 | EPS Estimate Current Year -0.61 | EPS Estimate Next Year -0.66 | Wall Street Target Price 69 | Quarterly Revenue Growth 6.167 |
The hype perspective for BB Biotech AG maps headline activity to recent price response and peer coverage.
The Triple Exponential Smoothing forecasted value of BB Biotech AG on the next trading day is expected to be 46.07 with a mean absolute deviation of 0.65 and the sum of the absolute errors of 39.06.BB Biotech after-hype prediction price | ₣ 46.11 |
Sentiment metrics here complement forecasting and technical views with analyst and earnings context.
BION |
BB Biotech Additional Predictive Modules
Predictive models for BB Biotech combine technical indicators with statistical methods to estimate probable price trajectories. No prediction model eliminates uncertainty; the goal is to identify scenarios with favorable risk-adjusted probabilities.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Triple Exponential Smoothing Price Forecast For the 18th of March 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of BB Biotech AG on the next trading day is expected to be 46.07 with a mean absolute deviation of 0.65 , mean absolute percentage error of 0.72 , and the sum of the absolute errors of 39.06 .Please note that although there have been many attempts to predict BION Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that BB Biotech's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest BB Biotech | BB Biotech Price Prediction | Research Analysis |
Forecasted Value
For the next trading day, Macroaxis evaluates BB Biotech's predictive range by looking for statistically meaningful downside and upside boundaries. The projected forecast band currently runs from roughly 44.27 on the downside to about 47.87 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of BB Biotech stock data series using in forecasting. Note that when a statistical model is used to represent BB Biotech stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | 0.1367 |
| MAD | Mean absolute deviation | 0.6509 |
| MAPE | Mean absolute percentage error | 0.0141 |
| SAE | Sum of the absolute errors | 39.0565 |
The mean reversion tendency in BB Biotech's price is a well-documented phenomenon that disciplined investors can exploit by identifying when price has diverged substantially from fundamental and historical anchors.
After-Hype Price Density Analysis
The probability distribution chart for BB Biotech displays the range and likelihood of predicted price outcomes based on BB Biotech's historical volatility and news impact patterns. Use the full distribution - not just the central estimate - to understand the true risk and reward.
Next price density |
| Expected price to next headline |
Estimiated After-Hype Price Volatility
The after-hype price analysis for BB Biotech uses BB Biotech's historical news coverage to estimate statistically significant upside and downside price boundaries for the session following a major headline.
Current Value
This after-hype projection for BB Biotech AG uses a 3 months horizon to examine how price may behave after short-term sentiment effects dissipate. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Price Outlook Analysis
Have you ever been surprised when a price of a Company such as BB Biotech is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading BB Biotech backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with BB Biotech, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.04 | 1.80 | 0.01 | 0.02 | 2 Events | 2 Events | In a few days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
46.10 | 46.11 | 0.02 |
|
Hype Timeline
BB Biotech AG is currently traded for 46.10on SIX Swiss Exchange of Switzerland. The company has historical hype elasticity of 0.01, and average elasticity to hype of competition of -0.02. BION is anticipated to increase in value after the next headline, with the price projected to jump to 46.11 or above. The average volatility of media hype impact on the company the price is over 100%. The price increase on the next news is anticipated to be 0.02%, whereas the daily expected return is currently at 0.04%. The volatility of related hype on BB Biotech is about 297.23%, with the expected price after the next announcement by competition of 46.08. The company reported revenue of 587.01 M. Net Income was 578.13 M with profit before overhead, payroll, taxes, and interest of 615.46 M. Assuming the 90-day trading horizon the next anticipated press release will be in a few days. Historical Fundamental Analysis of BB Biotech provides a cross-check on projections for BB Biotech. The historical view provides additional context.Related Hype Analysis
Analyzing BB Biotech's direct competitors. news reactions provides a leading indicator for how BB Biotech may respond to comparable market events. The peer hype analysis table captures key risk and sentiment metrics across BB Biotech's competitive set, helping investors anticipate.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| IDIA | Idorsia | -0.55 | 4 per month | 0.00 | -0.05 | 8.57 | -7.37 | 22.43 | |
| TECN | Tecan Group AG | -3.30 | 5 per month | 0.00 | -0.07 | 3.47 | -3.37 | 12.91 | |
| KURN | Kuros Biosciences AG | 0.48 | 2 per month | 0.00 | -0.10 | 3.84 | -4.78 | 19.40 | |
| BSLN | Basilea Pharmaceutica AG | -1.70 | 3 per month | 1.78 | 0.03 | 3.01 | -2.77 | 10.08 | |
| EVE | Evolva Holding SA | 0.00 | 0 per month | 4.61 | 0.05 | 8.00 | -10.31 | 25.46 | |
| SANN | Santhera Pharmaceuticals Holding | 0.66 | 4 per month | 2.88 | 0.1 | 6.30 | -5.06 | 18.11 | |
| MOLN | Molecular Partners AG | 0.16 | 6 per month | 3.15 | 0.01 | 6.16 | -4.10 | 19.98 | |
| ADXN | Addex Therapeutics | -0.0004 | 5 per month | 0.00 | -0.06 | 6.00 | -6.90 | 18.70 | |
| NWRN | Newron Pharmaceuticals SpA | -1.20 | 5 per month | 0.00 | -0.02 | 6.60 | -5.71 | 16.79 |
Other Forecasting Options for BB Biotech
For any investor considering BION, BB Biotech's price movement is the central factor in determining investment viability. The noise present in BION Stock price charts can distort investment decisions if not properly addressed.BB Biotech Related Equities
The following equities are related to BB Biotech within the Health Care space and can be used for peer comparison, relative valuation, or portfolio diversification. Comparing BB Biotech against peers on metrics such as P/E, margins, and return on equity helps contextualize its positioning and identify relative strengths or weaknesses.
| Risk & Return | Correlation |
BB Biotech Market Strength Events
Market strength indicators for BB Biotech stock help investors evaluate the security's behavior relative to ongoing market conditions. These tools support better market timing and help identify entry and exit signals for BB Biotech AG.
BB Biotech Risk Indicators
The analysis of BB Biotech's basic risk indicators is a key input for accurate price forecasting and sound investment decisions. Understanding the risk in BB Biotech's investment allows investors to make informed choices about accepting or mitigating that exposure.
| Mean Deviation | 1.36 | |||
| Semi Deviation | 1.71 | |||
| Standard Deviation | 1.76 | |||
| Variance | 3.1 | |||
| Downside Variance | 3.34 | |||
| Semi Variance | 2.93 | |||
| Expected Short fall | -1.52 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for BB Biotech
The amount of media and story coverage tied to BB Biotech AG can signal where market attention is concentrating at the moment. A disciplined read of coverage helps investors separate durable relevance from temporary noise.
Other Macroaxis Stories
Macroaxis publishes story content for a diverse readership that includes finance students, independent investors, money managers, and market-focused operating teams. What connects that audience is a focus on building stronger portfolios through better research, risk awareness, and comparative analysis.
Story Categories
Currently Trending Categories
BB Biotech Short Properties
Reviewing short-oriented indicators for BB Biotech AG is useful because long and short participants often create very different signals for timing and volatility. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
| Common Stock Shares Outstanding | 55.1 M | |
| Cash And Short Term Investments | 99.4 M |
Additional Tools for BION Stock Analysis
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |